<?xml version="1.0" encoding="UTF-8"?>
<ref id="rmv2143-bib-0088">
 <label>88</label>
 <mixed-citation publication-type="journal" id="rmv2143-cit-0088">
  <string-name>
   <surname>Zhang</surname>
   <given-names>C</given-names>
  </string-name>, 
  <string-name>
   <surname>Wu</surname>
   <given-names>Z</given-names>
  </string-name>, 
  <string-name>
   <surname>Li</surname>
   <given-names>J‐W</given-names>
  </string-name>, 
  <string-name>
   <surname>Zhao</surname>
   <given-names>H</given-names>
  </string-name>, 
  <string-name>
   <surname>Wang</surname>
   <given-names>GQ</given-names>
  </string-name>. 
  <article-title>The cytokine release syndrome (CRS) of severe COVID‐19 and Interleukin‐6 receptor (IL‐6R) antagonist Tocilizumab may be the key to reduce the mortality</article-title>. 
  <source xml:lang="en">Int J Antimicrob Agents</source>. 
  <year>2020</year>;
  <volume>55</volume>:
  <elocation-id>105954</elocation-id>
  <pub-id pub-id-type="pmid">32234467</pub-id>
 </mixed-citation>
</ref>
